FDA Updates Biosimilar Regulatory Research Program With Roadmap

February 02, 2023

The FDA published its research roadmap as part of the Biosimilars User Fee Act III regulatory research pilot program. The roadmap will allow stakeholders to see how the program will help the FDA enhance regulatory decision-making surrounding biosimilar development.

Biosimilar Rheumatology Roundup: January 2023
US Welcomes First Adalimumab Biosimilar, Amjevita
BioRationality: A Dr Sarfaraz Niazi Column—FDA Discloses Changes to Drug Review Process, Biosimilar Licensing
Seeing Eye to Eye: FDA's Dr Sarah Yim Discusses Efforts to Increase Confidence in Ophthalmology Biosimilars